Efficacy and Pharmacokinetics of Intravenous Immune Globulin Administration to High-Risk Neonates

Janet Kinney, Lucinda Mundorf, Robert H Yolken, Timothy Townsend

Research output: Contribution to journalArticle

Abstract

To determine whether intravenous immune globulin (IVIG) administration modifies the incidence of infections in high-risk neonates. —Randomized, double-blind study. —Neonatal intensive care unit at a tertiary care center. —A total of 170 infants were enrolled, 82 of whom received IVIG and 88 of whom received the placebo preparation. Infants were stratified by birth weight into one of three groups (category 1, those weighing less than 1000 g; category 2, those weighing between 1000 and 1500 g; and category 3, those weighing more than 1500 g). —Intravenous immune globulin (750 mg/kg of body weight), or albumin placebo was administered within 72 hours of admission to the tertiary care center and every 14 days thereafter until discharge from the neonatal intensive care unit or age 3 months. Serum IgG levels were measured and data collected relating to the incidence of systemic and localized infections and to the course of hospitalization. —The administration of IVIG had no major side effects and resulted in higher serum IgG levels in infants in all birth weight categories compared with infants receiving the placebo. Systemic infections developed in five IVIG-treated infants and five placebo-treated infants. Administration of immunoglobulin had no significant effect on the rate of localized infections or necrotizing enterocolitis. It also did not affect hospital course of the infants as measured by length of hospitalization or the number of days on assisted ventilation, supplemental oxygen, or antibiotics was required. —The general administration of IVIG using this dosage regimen has limited effects on the clinical course of infants in a neonatal intensive care unit.

Original languageEnglish (US)
Pages (from-to)1233-1238
Number of pages6
JournalAmerican Journal of Diseases of Children
Volume145
Issue number11
DOIs
StatePublished - 1991

Fingerprint

Intravenous Immunoglobulins
Pharmacokinetics
Newborn Infant
Neonatal Intensive Care Units
Placebos
Infection
Tertiary Care Centers
Birth Weight
Hospitalization
Immunoglobulin G
Necrotizing Enterocolitis
Incidence
Serum
Double-Blind Method
Ventilation
Immunoglobulins
Albumins
Body Weight
Oxygen
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Efficacy and Pharmacokinetics of Intravenous Immune Globulin Administration to High-Risk Neonates. / Kinney, Janet; Mundorf, Lucinda; Yolken, Robert H; Townsend, Timothy.

In: American Journal of Diseases of Children, Vol. 145, No. 11, 1991, p. 1233-1238.

Research output: Contribution to journalArticle

@article{a7590a2513d2419ba9f24a0bbbc2f9c5,
title = "Efficacy and Pharmacokinetics of Intravenous Immune Globulin Administration to High-Risk Neonates",
abstract = "To determine whether intravenous immune globulin (IVIG) administration modifies the incidence of infections in high-risk neonates. —Randomized, double-blind study. —Neonatal intensive care unit at a tertiary care center. —A total of 170 infants were enrolled, 82 of whom received IVIG and 88 of whom received the placebo preparation. Infants were stratified by birth weight into one of three groups (category 1, those weighing less than 1000 g; category 2, those weighing between 1000 and 1500 g; and category 3, those weighing more than 1500 g). —Intravenous immune globulin (750 mg/kg of body weight), or albumin placebo was administered within 72 hours of admission to the tertiary care center and every 14 days thereafter until discharge from the neonatal intensive care unit or age 3 months. Serum IgG levels were measured and data collected relating to the incidence of systemic and localized infections and to the course of hospitalization. —The administration of IVIG had no major side effects and resulted in higher serum IgG levels in infants in all birth weight categories compared with infants receiving the placebo. Systemic infections developed in five IVIG-treated infants and five placebo-treated infants. Administration of immunoglobulin had no significant effect on the rate of localized infections or necrotizing enterocolitis. It also did not affect hospital course of the infants as measured by length of hospitalization or the number of days on assisted ventilation, supplemental oxygen, or antibiotics was required. —The general administration of IVIG using this dosage regimen has limited effects on the clinical course of infants in a neonatal intensive care unit.",
author = "Janet Kinney and Lucinda Mundorf and Yolken, {Robert H} and Timothy Townsend",
year = "1991",
doi = "10.1001/archpedi.1991.02160110025013",
language = "English (US)",
volume = "145",
pages = "1233--1238",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Efficacy and Pharmacokinetics of Intravenous Immune Globulin Administration to High-Risk Neonates

AU - Kinney, Janet

AU - Mundorf, Lucinda

AU - Yolken, Robert H

AU - Townsend, Timothy

PY - 1991

Y1 - 1991

N2 - To determine whether intravenous immune globulin (IVIG) administration modifies the incidence of infections in high-risk neonates. —Randomized, double-blind study. —Neonatal intensive care unit at a tertiary care center. —A total of 170 infants were enrolled, 82 of whom received IVIG and 88 of whom received the placebo preparation. Infants were stratified by birth weight into one of three groups (category 1, those weighing less than 1000 g; category 2, those weighing between 1000 and 1500 g; and category 3, those weighing more than 1500 g). —Intravenous immune globulin (750 mg/kg of body weight), or albumin placebo was administered within 72 hours of admission to the tertiary care center and every 14 days thereafter until discharge from the neonatal intensive care unit or age 3 months. Serum IgG levels were measured and data collected relating to the incidence of systemic and localized infections and to the course of hospitalization. —The administration of IVIG had no major side effects and resulted in higher serum IgG levels in infants in all birth weight categories compared with infants receiving the placebo. Systemic infections developed in five IVIG-treated infants and five placebo-treated infants. Administration of immunoglobulin had no significant effect on the rate of localized infections or necrotizing enterocolitis. It also did not affect hospital course of the infants as measured by length of hospitalization or the number of days on assisted ventilation, supplemental oxygen, or antibiotics was required. —The general administration of IVIG using this dosage regimen has limited effects on the clinical course of infants in a neonatal intensive care unit.

AB - To determine whether intravenous immune globulin (IVIG) administration modifies the incidence of infections in high-risk neonates. —Randomized, double-blind study. —Neonatal intensive care unit at a tertiary care center. —A total of 170 infants were enrolled, 82 of whom received IVIG and 88 of whom received the placebo preparation. Infants were stratified by birth weight into one of three groups (category 1, those weighing less than 1000 g; category 2, those weighing between 1000 and 1500 g; and category 3, those weighing more than 1500 g). —Intravenous immune globulin (750 mg/kg of body weight), or albumin placebo was administered within 72 hours of admission to the tertiary care center and every 14 days thereafter until discharge from the neonatal intensive care unit or age 3 months. Serum IgG levels were measured and data collected relating to the incidence of systemic and localized infections and to the course of hospitalization. —The administration of IVIG had no major side effects and resulted in higher serum IgG levels in infants in all birth weight categories compared with infants receiving the placebo. Systemic infections developed in five IVIG-treated infants and five placebo-treated infants. Administration of immunoglobulin had no significant effect on the rate of localized infections or necrotizing enterocolitis. It also did not affect hospital course of the infants as measured by length of hospitalization or the number of days on assisted ventilation, supplemental oxygen, or antibiotics was required. —The general administration of IVIG using this dosage regimen has limited effects on the clinical course of infants in a neonatal intensive care unit.

UR - http://www.scopus.com/inward/record.url?scp=0025721168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025721168&partnerID=8YFLogxK

U2 - 10.1001/archpedi.1991.02160110025013

DO - 10.1001/archpedi.1991.02160110025013

M3 - Article

VL - 145

SP - 1233

EP - 1238

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 11

ER -